# Mankind Pharma (MANKIND) - Investment Analysis

**Stock:** Mankind Pharma Limited
**Sector:** Pharmaceuticals
**Exchange:** BSE

---

## Analysis History

---

## 2026-02-05 | HOLD + STRICT MONITORING ⭐⭐⭐

### Position Summary
- **Shares:** 100
- **Avg Price:** ₹2,290.33
- **Current:** ₹2,085.00
- **P&L:** -₹20,533 (-8.96%)
- **Investment:** ₹2,29,033

### Market Data
- Open: ₹2,089.75 | High: ₹2,100.90 | Low: ₹2,075
- Day Change: -₹4.70 (-0.22%)
- Volume: 1,675 (low)

### Q3 FY26 Results
**Revenue:** ₹3,567 Cr (+11.5% YoY) | 9M: ₹10,835 Cr (+18.7%) ✅
**Profit:** ₹414 Cr (+9.5% YoY) | 9M PAT: ₹1,379 Cr (-12.6% YoY) ⚠️
**Margins:** EBITDA 22.9% (down from 25.6%) - 270 bps decline ⚠️⚠️
**Debt:** Net debt ₹4,294 Cr (reducing)

### Key Strengths
1. ✅ Revenue growth 11-18% YoY
2. ✅ Strong distribution, chronic segment growth
3. ✅ Analyst targets ₹2,460 (18% upside)
4. ✅ BSV consolidation benefits

### Key Concerns - VALUATION TRAP RISK
1. ⚠️⚠️ **P/E 45x** vs peers (Sun: 30x, Cipla: 28x, Dr. Reddy's: 35x)
2. ⚠️⚠️ **50%+ premium** to peers WITHOUT justification
3. ⚠️⚠️ Margin compression despite revenue growth
4. ⚠️ Stock fell 4% on results (market concerned)

### Decision Rationale
**HOLD (not SELL yet) because:**
- Only 8.96% loss - small
- Q4 may show margin recovery
- Analyst support (₹2,460 target)
- Revenue growth healthy

**NOT ACCUMULATE because:**
- Valuation trap confirmed (45x P/E + declining margins)
- Premium unjustified vs peers
- Per criteria: HIGH RED FLAG

**Stop-Loss:** ₹1,950 (-15% protection)

### Action Taken
- ✅ GTT Stop-Loss: 100 shares @ ₹1,950 (Trigger ID: 305578263)

### Price Targets
- 3M: ₹2,150-2,200 (watch for exit) | 6M: ₹2,300-2,400 (partial exit)
- Analyst: ₹2,460 (12M) - Low confidence

### Next Review
- **April-May 2026:** Q4 FY26 results - CRITICAL
- **Watch:** EBITDA margin MUST recover >24%
- **Decision:** If margins stay <24% for Q4+Q1, EXIT
- **Partial Exit:** Consider selling 50 shares at ₹2,200-2,300 bounce

### Exit Criteria
- Margins <24% for 2 consecutive quarters
- P/E stays >40x while peers <35x
- Stop-loss ₹1,950 triggered

### Sources
- [Mankind shares drop 4% on Q3 results](https://www.business-standard.com/markets/news/mankind-pharma-shares-drop-4-even-as-q3-profit-rises-check-outlook-126020400389_1.html)
- [Mankind Q3 PAT up 9.5%, revenue rises 11.5%](https://www.business-standard.com/companies/quarterly-results/mankind-pharma-q3-pat-up-9-5-revenue-rises-11-5-on-chronic-sales-126020301366_1.html)
- [Mankind: Revenue Growth But Margins Squeeze](https://www.whalesbook.com/news/English/healthcarebiotech/Mankind-Pharma-Growth-Fuels-Revenue-But-Margins-Squeeze/6982e8dff5a3f0ebac99204c)

---

